English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
News
Explore the new CML Clinical Trials Resource on the iCMLf website
April 2025 - We’re excited to introduce a new resource from the iCMLf created to support the global CML community:
The iCMLf CML Clinical Trials Overview is now live!
Finding reliable, up-to-date information on clinical trials can be time-consuming and overwhelming. That’s why we’ve developed a dedicated webpage to simplify your search for trials investigating new compounds to treat CML.
We've compiled CML-specific listings from clinicaltrials.gov into a single, easy-to-navigate page - with a downloadable searchable spreadsheet to help tailor your search.
🔍 What you’ll find:
- Two categorised lists of CML trials:
• Recruiting now – Trials currently enrolling patients (and potentially sites)
• Not yet recruiting – Studies in preparation stages
Hepatitis B and CML survey extended for one more week! – Deadline April 24th
April 2024 - Thank you to everyone who shared their experiences in the iCMLf Hepatitis B Virus (HBV) and CML Screening and Management Survey.
Your contributions are essential to improving the understanding and management of Hepatitis B for people living with CML. This global collaboration - and the insights gained from your clinical practice - bring us one step closer to informing future recommendations and enhancing patient care.
Submissions are now open until April 24th to help close regional data gaps.
Second pediatric CML case review: TFR after 9 years on imatinib without prior DMR
April 2025 - We are pleased to share the second publication in our ongoing series of pediatric CML (pCML) case reviews from low and middle-income countries (LMICs). These cases reflect the complexities inherent in managing pCML in resource-limited settings and aim to provide a comprehensive discussion from various perspectives to enhance knowledge and improve patient outcomes.
The latest case, published in the March edition of Case Reports in Oncology Medicine, highlights a challenging case from Brazil. Experts discuss treatment discontinuation in a child with CML who has not achieved a sustained deep molecular response.
Recognising excellence in CML - Congratulations to the 2025 iCMLf prize winners
March 2025 - Every year, the iCMLf Prizes acknowledge individuals whose remarkable contributions have shaped the field of CML, driving progress in research, treatment, and care worldwide. This year, we celebrate three outstanding people whose work has transformed our understanding of CML biology, refined clinical management, and improved CML treatment and care in low- and middle-income countries.
We are delighted to announce the recipients of the 2025 iCMLf Prizes:
- Rowley Prize – Professor Satu Mustjoki (Finland)
- Goldman Prize – Dr. Delphine Rea (France)
- iCMLf Prize – Professor Nicholas Anthony Othieno-Abinya (Kenya)
25 Years of TKIs: A Timeline of Transformation
Twenty-five years ago, the landscape of chronic myeloid leukemia (CML) treatment changed forever with the introduction of tyrosine kinase inhibitors (TKIs). Before this breakthrough, CML was a life-threatening diagnosis, with limited treatment options such as interferon therapy or bone marrow transplantation. Today, thanks to TKIs, CML has transformed into a manageable condition, allowing patients to live full and productive lives.
Register Now: iCMLf Regional Discussion Groups - South Asia 2025
We are pleased to announce the first instalment of our 2025 South Asian regional program to address specific local challenges for physicians treating people with CML. We are starting this year's progam of three zoom-based Regional Discussion Groups on April 23rd.
